Newleos Therapeutics receives $15.5M grant from NIDA/NIH to advance NTX-2001 for cocaine and alcohol use disorders through clinical trials.
Amount Raised
$15.5 Million
Round Type
Grant
BostonBiotechnologyHealth CareTherapeuticsInvestors
Description
Newleos Therapeutics, a Boston-based clinical-stage biotech company, received a $15.5M grant from the National Institute on Drug Abuse (NIDA), part of the NIH. The funding will support development of NTX-2001 in cocaine use disorder through Phase 1 drug-drug interaction and Phase 2 efficacy studies. The company is also conducting Phase 1b studies for alcohol use disorder and holds FDA Fast Track designation for NTX-2001 in AUD. Newleos focuses on neuropsychiatric mechanisms targeting multiple ion channels to reduce side effects and improve treatment outcomes.
Who to call at Newleos Therapeutics, and when
A new round usually means Newleos Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Newleos Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Newleos Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Newleos Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Newleos Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Newleos Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.